Patients admitted for study under this protocol will be registered with the 
principal investigator at Building 10, Room 5D37, National Institutes of Health, 
Bethesda, MD. 20892. [(301)496-2239,496-5728]. 
Exclusion Criteria: Patients with the following conditions will be excluded from the 
study: 
1 . Impairment of renal function. Patients must have a creatinine of less than 1 .5 mg% 
or creatinine clearance greater than 80 ml/min/m 2 . 
2. Coagulopathy. Patients must have a normal coagulation profile as demonstrated by 
normal Prothrombin Time (PT) and activated Partial Thromboplastin Time (PTT). 
3. Acute infection. Active infection is defined as any acute viral, bacterial or fungal 
infection which requires specific therapy. 
4. Neurological deterioration. Patients with an increased ICP who require prompt 
reduction of ICP and have a surgically inaccessible lesion will be excluded. 
5. HIV positive patients . 
6. Pr egnant . patients, 
7. Thrombocytopenia. Platelet count < 100,000 platelets /mm 3 
8. Granulocytopenia, anc < iooo/mm 3 
9. Severe systemic diseases such as severe ischemic heart or lung disease 
considered to be associated with an unacceptable anesthetic/operative risk. 
10. Patients with Karnofskv Score below 20 (see appendix) will be excluded from the 
study, (see appendix H). 
11. Despite the requirement for a Durable Power of Attorney, as appears in the informed 
consent, patients who are unable to comprehend and sign the informed consent will 
be excluded from the study. 
IV. Clinical Evaluation Before Treatment 
A. Before a patient can be entered into this study, the NIH investigators must receive 
information from the referring physician(s) detailing the clinical history, general 
laboratory results, specific neurologic and radiologic evaluations, their diagnoses, 
and all previous therapies (Appendix A). 
[806] 
Recombinant DNA Research, Volume 15 
